FGFR1 and FGFR4 are essential regulators of muscle stem cell quiescence Authors: Chung-Ju Yeh, Kiran Nakka, Zipora Yablonka-Reuveni, Christoph Lepper Published: 2025 ABSTRACT Quiescence – the reversible growth-arrested G0 state – is critical for the long-term maintenance of many adult stem cells and hence the tissues’ life-long regenerative capacity. Failure to maintain stem cell quiescence during aging leads to stem cell loss and reduced ability to regenerate after injury. However, our knowledge about the complex molecular signaling networks required for maintaining stem cells in quiescence is incomplete. Here, we discovered an essential role for FGFR1 and FGFR4 in regulating skeletal muscle stem cell, i.e. satellite cell (SC), quiescence via inhibiting their precocious differentiation. Moreover, SC-specific Fgfr1/4-deficiency results in impaired muscle regeneration and decreased SC self-renewal. Our data reveal that the activated Fgfr1/4-deficient SC-lineage prematurely exits the cell cycle and undergoes terminal differentiation, which is regulated via the ERK signaling axis. This study advances our foundational knowledge on the molecular mechanisms governing SC quiescence, and reveals FGFR1/4 as promising therapeutic targets with the potential to enhance regenerative outcomes in skeletal muscle repair.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12964-025-02533-0. Introduction Cellular quiescence — a reversible, cell cycle-arrested state — is crucial for the long-term maintenance of many adult stem cells, including satellite cells (SCs) in skeletal muscle tissue [1]. The molecular mechanisms responsible for maintenance of this quiescent state are therefore critical for preserving the tissues’ regenerative capacity throughout life. Although recent discoveries are beginning to unravel a complex interplay of SC intrinsic and extrinsic molecular regulators required for SC quiescence maintenance [2–10], our understanding of these complex molecular networks is still incomplete. SCs are ‘bona fide’ muscle stem cells that reside under the basal lamina of skeletal muscle fibers [11]. They are the essential source of new myonuclei for postnatal muscle growth and acute injury-induced regeneration [12–18]. Under normal conditions in the adult, myonuclei turnover rate is relatively low, and SCs are maintained in quiescence [10]. Upon acute injury, SCs readily break quiescence, become activated, enter into rapid proliferation cycles and ultimately differentiate and fuse to regenerate the damaged muscle fiber syncytia [19]. During regeneration, cell cycle withdrawal and return to the quiescent stem cell state must occur in a subset of SCs for reserving of the regenerative capacity of skeletal muscle tissue, which is termed stem cell self-renewal. However, the numbers of quiescent SCs decline with age [20–22], leading to decreased muscle regeneration capacities. Failure to maintain the quiescent state of SCs during aging is emerging as a major contributor to the decline in quiescent SCs, as several molecular regulators of SC quiescence including Notch are disturbed during aging [23–25]. Hence, it is imperative to comprehensively elucidate the molecular mechanisms required for maintaining SCs in quiescence, in order to develop novel, targeted strategies to enhance skeletal muscle regeneration in the elderly. The 18 canonical Fibroblast Growth Factors (FGF) are members of the evolutionarily conserved FGF family and function as secretory cell signaling proteins. They play fundamental roles in many biological processes, including organ morphogenesis and angiogenesis during embryogenesis, as well as tissue homeostasis and repair in adulthood [26–29]. They require the cofactors heparin or heparin sulfate to bind to their cognate FGF Receptor (FGFR) transmembrane tyrosine kinases [30]. FGF ligand binding to FGFR stimulates receptor tyrosine kinase dimerization and trans-phosphorylation, which results in downstream signaling pathway activation (such as Akt and ERK) to regulate cellular processes including survival, proliferation, migration, or differentiation [28, 31, 32]. FGF Signaling has also been implicated in regulating myogenic progenitor cells in both embryonic development and during adult muscle regeneration. For example, FGF2 can promote myoblast proliferation and inhibit differentiation in vitro, and FGF6 is essential for full regenerative capacity and SC pool size [33–40]. Meanwhile, ectopic expression of a dominant negative FGFR during chick limb development results in reduced skeletal muscle mass [41]. However, the functions of FGFRs in adult SCs are not well understood [42, 43]. Whether FGFR signaling has a role in regulating SC quiescence is also unknown. Of the 4 FGFRs, SCs predominantly express FGFR1 and FGFR4, with very low or undetectable expression levels of FGFR2 and FGFR3 [42, 44, 45]. Surprisingly, neither Fgfr1 nor Fgfr4 loss-of-function studies in the mouse revealed substantial contributions of either gene to SC regulation or skeletal muscle regeneration. Conditional Fgfr1 inactivation in the myogenic lineage had no significant impact on SC numbers, and regenerative capacity was unaffected, though regeneration kinetics were slightly delayed [42]. Fgfr4 inactivation resulted in only a mild muscle regeneration defect of unclear cellular origin due to Fgfr4 gene disruption in all cells [46]. As FGFR1 and FGFR4 have matching high affinities to a similar complement of FGF ligands [47] and different FGFRs have been shown to heterodimerize [44, 48–50], we hypothesize that the rather mild muscle phenotypes observed in the individual Fgfr1 and Fgfr4 gene inactivation studies in the mouse stem from compensatory activity of the remaining intact Fgfr family member. Here, we unravel a surprising role for FGFR1 and FGFR4 in maintaining the quiescent SC pool during homeostasis and orchestrating SC-lineage amplification during injury-induced muscle regeneration. Taking a genetic approach for dual inactivation of both Fgfr1 and Fgfr4 specifically in adult SCs, we find that Fgfr1/4-deficient SCs spontaneously break quiescence and terminally differentiate, resulting in a progressive decline in SC numbers during homeostasis. Upon muscle injury, Fgfr1/4 dual inactivation results in compromised muscle regeneration and reduced SC self-renewal. Mechanistically, we discover that FGFR1 and FGFR4 coordinate SC lineage amplification via blocking cell cycle exit and differentiation, which is mediated by the ERK signaling pathway. Taken together, these findings demonstrate that SC-specific FGFR1/4 signaling is essential for governing SC quiescence and hence, the remarkable life-long ability of skeletal muscle tissue to repeatedly regenerate upon injury, providing potential therapeutic targets to improve muscle regeneration. Results Fgfr1 and Fgfr4 are required for quiescent SC pool maintenance To investigate the combined contributions of Fgfr1 and Fgfr4 to SC regulation, we generated a mouse model for inducible (via tamoxifen) dual inactivation of both Fgfr1 and Fgfr4 specifically in the SC lineage by combining the Pax7CreERT2 knockin allele (Pax7CE) with floxed Fgfr1 (Fgfr1flox) and Fgfr4 (FgfrR4flox) alleles (Figure S1A). A Cre reporter allele (Rosa26eYFP) was included for concomitant labeling of Pax7-expressing cells via YFP. Tamoxifen injections were performed on both control (Pax7CE/+;Fgfr1+/+;Fgfr4+/+;Rosa26eYFP/eYFP, i.e. ‘Control’) and SC-specific Fgfr1/4 knockout (Pax7CE/+;Fgfr1flox/flox;Fgfr4flox/flox;Rosa26eYFP/eYFP, i.e. ‘FGFR1/4 KO’) mice to induce loxP recombination events at respective conditional gene loci in adult (3–6 months) SCs. High recombination rates were confirmed at both Rosa26eYFP reporter allele (via PAX7/YFP dual immunofluorescence (IF) labeling of freshly isolated single myofibers, i.e. > 95% PAX7+/YFP+ out of total PAX7+ cells) and Fgfr1 (via PAX7/FGFR1 dual IF, i.e. > 97% PAX7+/FGFR1− out of total PAX7+ cells) alleles at one week after tamoxifen administration (Figure S1B-D). In the absence of an IF-grade anti-FGFR4 antibody, we confirmed recombination of the ‘floxed’ Fgfr4 alleles by reverse transcriptase PCR using mRNA from cultured primary myoblasts isolated via Fluorescence-Activated Cell Sorting (Figure S1E). First, we investigated contributions by Fgfr1/4 to SC maintenance over time. For this, we quantified PAX7+ SCs in the tibialis anterior (TA) muscle and found that 2 weeks, 4 weeks, and 6 months after Fgfr1/4 dual inactivation, SC numbers decreased by 42%, 56%, and 74%, respectively (Fig. 1A, B). To confirm this depletion of the SC pool, we performed YFP/PAX7 double IF staining on soleus muscle tissue Sects. 35 days after Fgfr1/4 inactivation. In our mouse model, tamoxifen-induced loxP recombination at the Rosa26 locus results in permanent YFP expression, thereby enabling SC lineage tracing independent of Pax7 expression status. We observed no significant changes in the percentage of PAX7+ cells within the YFP-expressing population. Consistently, we found that the number of YFP-lineage–marked cells declined in parallel with the reduction of PAX7+ cells in the FGFR1/4 KO group (Fig. 1C ~ F). These data demonstrate that Pax7 expression is not affected by inactivation of Fgfr1/4 in SCs and confirm that Fgfr1 and Fgfr4 are essential for quiescent SC pool maintenance.Fig. 1Fgfr1 and Fgfr4 are required for quiescent SC pool maintenance. A Representative dual anti-PAX7/anti-Laminin IF staining on 10 μm cryosections from Control (Left) and FGFR1/4 KO (Right) TA muscles 4 weeks after Fgfr1/4 inactivation by tamoxifen. Individual images for PAX7 (top panels) and pseudo-colored merged overlays (bottom panels; Green: PAX7, Red: Laminin, Blue: DAPI) are shown. Arrows: PAX7+ SCs. Scale bar (top right panel): 50 μm. B Quantification of SC numbers (PAX7+ cells) in the uninjured TA muscles at different timepoints after Fgfr1/4 inactivation. (n = 4 biological replicates for each timepoint and genotype; 2 weeks: all male mice; 4 weeks: 1 female and 3 males for Control, 2 females and 2 males for FGFR1/4 KO; 6 months: all female mice; 10 random 0.15mm2 images analyzed in each n. Analyzed by 2-tailed two-sample t-test. 2 weeks: p = 0.0107; 4 weeks: p = 0.0032, 6 months: p = 0.0013). C Representative dual anti-YFP/anti-PAX7 IF staining on 10 μm cryosections from Control (Left) and FGFR1/4 KO (Right) soleus muscles 35 days after Fgfr1/4 inactivation by tamoxifen. Individual images for YFP, PAX7, DAPI and pseudo-colored merged overlays (Green: YFP, Red: PAX7, Blue: DAPI) are shown. Arrows: YFP+/PAX7+ SCs. Scale bar (top right panel): 50 μm. D-F Quantification of YFP+ cells (D), PAX7+ cells (E), and percentage of PAX7 + cells in all YFP + cells (F) in the uninjured soleus muscles 35 days after Fgfr1/4 inactivation. (Control: 4 biological replicates, FGFR1/4 KO: 6 biological replicates, all male mice; analyzed by 2-tailed two-sample t-test; YFP+: p = 0.034, PAX7+: p = 0.013, ns: not significant). G Quantification of percentage of YFP+ SCs among all singlet, mononuclear cells in TA and Gastrocnemius muscles by flow cytometry analysis (n = 3 biological replicates in each group; analyzed by 2-tailed two-sample t-test; TA: p = 0.072, Gastrocnemius: p = 0.049). H Representative anti-Myogenin/anti-YFP IF staining of isolated single muscle fibers from Control (Left) and FGFR1/4 KO (Right) mice 7 days after Fgfr1/4 inactivation by tamoxifen in vivo. Individual images for YFP, Myogenin, DAPI and pseudo-colored merged overlays (Green: YFP, Red: Myogenin, Blue: DAPI) are shown. Arrows: YFP+ SCs. Scale bar (top right panel): 50 μm. I Quantification of Myogenin.+ SCs in (C) (n = 3 biological replicates for each genotype, 52 ~ 96 SCs quantified for each n. Analyzed by 2-tailed two-sample t-test. p = 0.0283) Fgfr1 and Fgfr4 are required for quiescent SC pool maintenance. A Representative dual anti-PAX7/anti-Laminin IF staining on 10 μm cryosections from Control (Left) and FGFR1/4 KO (Right) TA muscles 4 weeks after Fgfr1/4 inactivation by tamoxifen. Individual images for PAX7 (top panels) and pseudo-colored merged overlays (bottom panels; Green: PAX7, Red: Laminin, Blue: DAPI) are shown. Arrows: PAX7+ SCs. Scale bar (top right panel): 50 μm. B Quantification of SC numbers (PAX7+ cells) in the uninjured TA muscles at different timepoints after Fgfr1/4 inactivation. (n = 4 biological replicates for each timepoint and genotype; 2 weeks: all male mice; 4 weeks: 1 female and 3 males for Control, 2 females and 2 males for FGFR1/4 KO; 6 months: all female mice; 10 random 0.15mm2 images analyzed in each n. Analyzed by 2-tailed two-sample t-test. 2 weeks: p = 0.0107; 4 weeks: p = 0.0032, 6 months: p = 0.0013). C Representative dual anti-YFP/anti-PAX7 IF staining on 10 μm cryosections from Control (Left) and FGFR1/4 KO (Right) soleus muscles 35 days after Fgfr1/4 inactivation by tamoxifen. Individual images for YFP, PAX7, DAPI and pseudo-colored merged overlays (Green: YFP, Red: PAX7, Blue: DAPI) are shown. Arrows: YFP+/PAX7+ SCs. Scale bar (top right panel): 50 μm. D-F Quantification of YFP+ cells (D), PAX7+ cells (E), and percentage of PAX7 + cells in all YFP + cells (F) in the uninjured soleus muscles 35 days after Fgfr1/4 inactivation. (Control: 4 biological replicates, FGFR1/4 KO: 6 biological replicates, all male mice; analyzed by 2-tailed two-sample t-test; YFP+: p = 0.034, PAX7+: p = 0.013, ns: not significant). G Quantification of percentage of YFP+ SCs among all singlet, mononuclear cells in TA and Gastrocnemius muscles by flow cytometry analysis (n = 3 biological replicates in each group; analyzed by 2-tailed two-sample t-test; TA: p = 0.072, Gastrocnemius: p = 0.049). H Representative anti-Myogenin/anti-YFP IF staining of isolated single muscle fibers from Control (Left) and FGFR1/4 KO (Right) mice 7 days after Fgfr1/4 inactivation by tamoxifen in vivo. Individual images for YFP, Myogenin, DAPI and pseudo-colored merged overlays (Green: YFP, Red: Myogenin, Blue: DAPI) are shown. Arrows: YFP+ SCs. Scale bar (top right panel): 50 μm. I Quantification of Myogenin.+ SCs in (C) (n = 3 biological replicates for each genotype, 52 ~ 96 SCs quantified for each n. Analyzed by 2-tailed two-sample t-test. p = 0.0283) To determine whether the decrease in SC numbers caused by loss of FGFR1/4 is a general phenotype among different muscle groups, we harvested different muscle groups (TA and gastrocnemius) separately to analyze the YFP+ myoblast fraction by flow cytometry. We recorded 1 million events from each sample and quantified the percentage of YFP+ cells among the singlet, mononuclear cell fractions. We found that the percentage of YFP+ cells was significantly reduced in the gastrocnemius and showed a trend toward reduction in the TA in the FGFR1/4 KO compared to Control group (Fig. 1G and S2A). Taken together with the in situ quantification of SCs in TA (Fig. 1B) and soleus (Fig. 1D, E) tissue sections via IF stainings, these data demonstrate that FGFR1/4 are required for maintaining the quiescent SC pool across different hindlimb muscle groups. To understand the cellular mechanism causing the decrease in SCs after Fgfr1/4 dual inactivation, we hypothesized that the quiescent FGFR1/4 KO SCs either precociously differentiate or undergo apoptosis. To determine whether FGFR1/4 KO SCs die via apoptosis, we performed IF stainings via the apoptotic marker cleaved caspase-3 (data not shown) and TUNEL assays on Control and FGFR1/4 KO TA muscle sections at 10 days post tamoxifen injections (Figure S2B). We did not detect any apoptotic SCs by either method in any of our samples. To determine whether FGFR1/4 KO SCs precociously differentiate, we freshly isolated single muscle fibers and performed dual IF staining for YFP (lineage-labeled SCs) and Myogenin (terminal myogenic differentiation marker). We performed this assay on single myofibers as preserving YFP in muscle sections requires a muscle wholemount paraformaldehyde fixation protocol that is incompatible with anti-Myogenin IF. Importantly, the YFP lineage reporter allows for unequivocal identification of the PAX7+-cell lineage even if cells lose Pax7 expression. By contrast to the Control, which had almost no Myogenin expression in the SC lineage (~ 0.34%), ~ 15% of the Fgfr1/4 dually deficient SC lineage-derived cells were Myogenin positive (Fig. 1H, I). These results show that FGFR1/4 KO SCs fail to maintain the undifferentiated quiescent state and undergo precocious differentiation. Given the prolonged time required for lineage progression from a quiescent SC to a terminally differentiated Myogenin-expressing myocyte, the brief duration of the single myofiber isolation procedure cannot account for SCs breaking quiescence and differentiating ex vivo. Accordingly, almost no Myogenin+ SCs were detected in our Control group. Thus, these findings provide compelling evidence that Fgfr1/4-deficient SCs must have exited quiescence and at least initiated –if not completed– differentiation in vivo. Skeletal muscle regeneration is compromised after acute Fgfr1/4 dual inactivation in SCs We next examined whether regenerative capacity is altered by Fgfr1/4 dual inactivation in SCs. To minimize the impact of decreased SC numbers on muscle regeneration in FGFR1/4 KO muscles, we chose an injury time point acutely after tamoxifen injections when SC numbers are still similar in the FGFR1/4 KO compared to the Control (Figure S3A). Control and FGFR1/4 KO mice were injured by cardiotoxin injection into the TA muscles 7 days after Fgfr1/4 dual inactivation (Fig. 2A). Muscle tissues were harvested and analyzed by histology and immunofluorescence stainings on TA cross Sects. 7- and 28-days post injury (DPI). We first confirmed robust, widespread injury in both the Control and FGFR1/4 KO groups by histological staining at 28 DPI (Figure S3B). At 7 DPI, no significant differences in regenerated muscle fiber cross-sectional area were observed between the Control and FGFR1/4 KO (Figure S3C-E). By contrast, at 28 DPI, the regenerated muscle fiber cross-sectional area was significantly decreased in the FGFR1/4 KO compared to the Control (Fig. 2B-D). We next asked whether early regenerative myotube formation is impaired in the FGFR1/4 KO group. To address this, we performed embryonic myosin heavy chain (eMyHC) IF staining on 4 DPI tissue sections (Figure S3F). Quantification revealed no significant differences between the groups in either the number of eMyHC+ fibers (normalized to injury area; Figure S3G) or their cross-sectional area (Figure S3H), indicating that Fgfr1/4-deficient SCs generate regenerative myotubes in numbers and sizes comparable to controls. We also examined self-renewal of Fgfr1/4 dually deficient SCs via EdU-labeling of proliferating cells during early regeneration timepoints and co-labeling with anti-PAX7 IF staining at 28 DPI. The numbers of self-renewed SCs (PAX7+/EdU+ cells) were significantly decreased in FGFR1/4 KO compared to Control regenerated TA muscles (Fig. 2E, F). These data demonstrate that both muscle regeneration and SC self-renewal are impaired after Fgfr1/4 dual inactivation in SCs.Fig. 2Skeletal muscle regeneration is compromised after acute Fgfr1/4 dual inactivation in SCs. A Experimental design for Fgfr1/4 inactivation via tamoxifen and muscle injury via intra-muscular cardiotoxin injection. Mice were injected with tamoxifen for 5 successive days. 7 days after the last tamoxifen injection, cardiotoxin was injected into TA muscles to create muscle injury. Muscle tissues were harvested 28 days post injury. B Representative Hematoxylin & Eosin stainings on 10 μm cryosections of the regenerative TA muscles from Control (Left) and FGFR1/4 KO (Right) mice 28 days post injury. Scale bar (top right panel): 100 μm. C Representative anti-Laminin IF staining on 10 μm cryosections of the injured muscles from Control (Left) and FGFR1/4 KO (Right) mice 28 days post injury. Pseudo-colored merged overlays (Red: Laminin, Blue: DAPI) are shown. Scale bar (top right panel): 100 μm. D Quantification of regenerated muscle fiber cross-sectional area (Control: n = 5 muscles, FGFR1/4 KO: n = 8 muscles; all male mice. Analyzed by 2-tailed two-sample t-test. p = 0.0359). E Representative anti-PAX7/anti-Laminin IF staining combined with EdU detection on 10 μm cryosections of regenerated TA muscles from Control (Left) and FGFR1/4 KO (Right) mice 28 days post injury. Individual images for PAX7, Laminin, EdU and pseudo-colored merged overlays (Green: PAX7, Red: Laminin, White: EdU, Blue: DAPI) are shown. Arrows: PAX7+EdU+ SCs. Scale bar (top right panel): 20 μm. F Quantification of self-renewed SCs (Pax7+/EdU.+ cells) 28 days post injury (Control: n = 5 biological replicates, FGFR1/4 KO: n = 8 biological replicates, all male mice. Analyzed by 2-tailed two-sample t-test. p < 0.001) Skeletal muscle regeneration is compromised after acute Fgfr1/4 dual inactivation in SCs. A Experimental design for Fgfr1/4 inactivation via tamoxifen and muscle injury via intra-muscular cardiotoxin injection. Mice were injected with tamoxifen for 5 successive days. 7 days after the last tamoxifen injection, cardiotoxin was injected into TA muscles to create muscle injury. Muscle tissues were harvested 28 days post injury. B Representative Hematoxylin & Eosin stainings on 10 μm cryosections of the regenerative TA muscles from Control (Left) and FGFR1/4 KO (Right) mice 28 days post injury. Scale bar (top right panel): 100 μm. C Representative anti-Laminin IF staining on 10 μm cryosections of the injured muscles from Control (Left) and FGFR1/4 KO (Right) mice 28 days post injury. Pseudo-colored merged overlays (Red: Laminin, Blue: DAPI) are shown. Scale bar (top right panel): 100 μm. D Quantification of regenerated muscle fiber cross-sectional area (Control: n = 5 muscles, FGFR1/4 KO: n = 8 muscles; all male mice. Analyzed by 2-tailed two-sample t-test. p = 0.0359). E Representative anti-PAX7/anti-Laminin IF staining combined with EdU detection on 10 μm cryosections of regenerated TA muscles from Control (Left) and FGFR1/4 KO (Right) mice 28 days post injury. Individual images for PAX7, Laminin, EdU and pseudo-colored merged overlays (Green: PAX7, Red: Laminin, White: EdU, Blue: DAPI) are shown. Arrows: PAX7+EdU+ SCs. Scale bar (top right panel): 20 μm. F Quantification of self-renewed SCs (Pax7+/EdU.+ cells) 28 days post injury (Control: n = 5 biological replicates, FGFR1/4 KO: n = 8 biological replicates, all male mice. Analyzed by 2-tailed two-sample t-test. p < 0.001) FGFR1/4 regulate the balance between proliferation and differentiation in SC-derived myoblasts To determine the cellular mechanism responsible for impaired muscle regeneration in FGFR1/4 KO mice, we applied the single myofiber culture assay to investigate FGFR1/4 KO SC proliferation and cell fate choice within the sublaminal SC niche. When single muscle fibers are placed in floating culture, SCs on the fibers activate, proliferate and undergo asymmetric stem cell divisions [51]. To elucidate the role of FGFR1/4 in SC proliferation, we used EdU to detect cells in S phase and found a significant decrease in EdU+ SCs in on myofibers at 72 h post isolation from FGFR1/4 KO mice compared to the Control (Fig. 3A, B). Next, we investigated SC fate choice at 72 h of culture. Using Myogenin as a terminal differentiation marker, we found a significant increase in the number of terminally differentiated SCs on FGFR1/4 KO compared to Control myofibers (Fig. 3C, D). These data prompted us to further probe whether FGFR1/4 KO myoblasts are more prone to differentiate. For this, we isolated SCs from FGFR1/4 KO and Control mice via Fluorescent Activated Cell Sorting for primary myoblast monolayer culture. Despite maintaining myoblasts in growth media, FGFR1/4 KO myoblast cultures had significantly greater percentage (~ 47%) of myoblasts fusing into myotube syncytia compared to Control cultures (~ 6%) (Fig. 3E, F). These data suggest that FGFR1/4 regulate the balance between proliferation and differentiation in the activated SC-lineage.Fig. 3FGFR1/4 regulate the balance between proliferation and differentiation in SC-derived myoblasts. A Representative anti-MYOD IF stainings combined with EdU detection of SCs on isolated single muscle fibers from Control (Left) and FGFR1/4 KO (Right) mice 21 days after Fgfr1/4 inactivation. Isolated myofibers were cultured for 72 h and EdU was applied to culture medium 4 h before fixation experiment endpoint. Individual images for MYOD, EdU, DAPI and pseudo-colored merged overlays (Green: MYOD, Red: EdU, Blue: DAPI) are shown. Scale bar (top right panel): 50 μm. B Quantification of SCs in S phase (MYOD+/EdU+ cells out of total MYOD+ cells) in (A) (Control: 153 SC clones, FGFR1/4 KO: 106 SC clones. Analyzed by 2-tailed two-sample t-test. p < 0.001). C Representative anti-MYOD/anti-Myogenin IF stainings of SCs on isolated single muscle fibers from Control (Left) and FGFR1/4 KO (Right) mice 21 days after Fgfr1/4 inactivation. Isolated fibers were cultured for 72 h. Individual images for MYOD, Myogenin, DAPI and pseudo-colored merged overlays (Green: MYOD, Red: Myogenin, Blue: DAPI) are shown. Scale bar (top right panel): 50 μm. D Quantification of terminally differentiated SCs (MYOD+/Myogenin+ cells out of total MYOD.+ cells) in (C) (Control: 153 SC clones, FGFR1/4 KO: 106 SC clones. Analyzed by 2-tailed two-sample t-test. p < 0.001). E Representative anti-MyHC/anti-Desmin IF stainings of SC-derived primary myoblasts isolated via FACS from Control (Left) and FGFR1/4 KO (Right) mice cultured in growth media. Cells were seeded in each well of a 24-well plate at 40% confluency. Pseudo-colored merged overlays (Green: MyHC, Orange: Desmin, Blue: DAPI) are shown. Scale bar (top right panel): 100 μm. F Quantification of fusion index in (E) (Control: n = 4 biological replicates, FGFR1/4 KO: n = 3 biological replicates; 445 ~ 907 nuclei quantified in each n. Analyzed by 2-tailed two-sample t-test. p < 0.001) FGFR1/4 regulate the balance between proliferation and differentiation in SC-derived myoblasts. A Representative anti-MYOD IF stainings combined with EdU detection of SCs on isolated single muscle fibers from Control (Left) and FGFR1/4 KO (Right) mice 21 days after Fgfr1/4 inactivation. Isolated myofibers were cultured for 72 h and EdU was applied to culture medium 4 h before fixation experiment endpoint. Individual images for MYOD, EdU, DAPI and pseudo-colored merged overlays (Green: MYOD, Red: EdU, Blue: DAPI) are shown. Scale bar (top right panel): 50 μm. B Quantification of SCs in S phase (MYOD+/EdU+ cells out of total MYOD+ cells) in (A) (Control: 153 SC clones, FGFR1/4 KO: 106 SC clones. Analyzed by 2-tailed two-sample t-test. p < 0.001). C Representative anti-MYOD/anti-Myogenin IF stainings of SCs on isolated single muscle fibers from Control (Left) and FGFR1/4 KO (Right) mice 21 days after Fgfr1/4 inactivation. Isolated fibers were cultured for 72 h. Individual images for MYOD, Myogenin, DAPI and pseudo-colored merged overlays (Green: MYOD, Red: Myogenin, Blue: DAPI) are shown. Scale bar (top right panel): 50 μm. D Quantification of terminally differentiated SCs (MYOD+/Myogenin+ cells out of total MYOD.+ cells) in (C) (Control: 153 SC clones, FGFR1/4 KO: 106 SC clones. Analyzed by 2-tailed two-sample t-test. p < 0.001). E Representative anti-MyHC/anti-Desmin IF stainings of SC-derived primary myoblasts isolated via FACS from Control (Left) and FGFR1/4 KO (Right) mice cultured in growth media. Cells were seeded in each well of a 24-well plate at 40% confluency. Pseudo-colored merged overlays (Green: MyHC, Orange: Desmin, Blue: DAPI) are shown. Scale bar (top right panel): 100 μm. F Quantification of fusion index in (E) (Control: n = 4 biological replicates, FGFR1/4 KO: n = 3 biological replicates; 445 ~ 907 nuclei quantified in each n. Analyzed by 2-tailed two-sample t-test. p < 0.001) To determine whether the increased propensity towards differentiation at the expense of proliferation in the FGFR1/4 KO group arises from loss of FGFR1/4 function during the activated stage, rather than from defects established earlier during quiescence, we inactivated Fgfr1/4 after single myofiber isolation. Specifically, 4-hydroxytamoxifen was administered following isolation and fibers were cultured for 72 h. Under these conditions, FGFR1/4 KO SCs exhibited markedly reduced proliferation and increased differentiation compared with controls (Figure S4A–D). These results demonstrate that FGFR1/4 regulate the balance between proliferation and differentiation in the activated SC lineage, independently of their roles during the quiescent stage. FGFR1/4 predominantly signal through the ERK effector pathway to drive SC proliferation and prevent precocious differentiation To investigate the molecular mechanism by which FGFR1/4 are promoting myoblast proliferation and preventing their differentiation, we examined the activity of known downstream effectors of FGFR1/4 including ERK1/2 and Akt by determining the ratios of phosphorylated over total proteins. Western blot analysis revealed that phosphorylated ERK1/2 significantly decreased in isolated FGFR1/4 KO myoblasts compared to Control myoblasts, while no significant change in phosphorylated Akt was detected. This indicates that FGFR1/4 may utilize the ERK signaling pathway to promote proliferation of the SC lineage (Fig. 4A). To determine whether the ERK signaling axis is indeed responsible for driving SC proliferation, we took a pharmacological approach to attempt to rescue the FGFR1/4 KO precocious differentiation phenotype via either forced ERK or Akt phosphorylation. For this, we applied either ERK activator (phorbol 12-myristate 13-acetate, PMA) and Akt activator (SC79) to the culture medium of (Z)−4-hydroxytamoxifen treated (to inactivate Fgfr1/4 in cultured myoblasts) FGFR1/4 KO myoblasts. Activation of ERK largely rescued Fgfr1/4 dually deficient myoblasts from precocious differentiation, while activation of Akt had no significant impact (Fig. 4B, C). Taken together, these data provide evidence that FGFR1/4 maintain proliferation and prevent precocious differentiation of myoblasts through the ERK signaling pathway.Fig. 4FGFR1 and FGFR4 predominantly signal through the ERK effector pathway to drive SC proliferation and prevent precocious differentiation. A Western blotting on total protein extracts from in vitro cultured SC-derived primary myoblasts isolated via FACS from Control (Left) and FGFR1/4 KO (Right) mice. Phospho-ERK and phospho-AKT signals were detected by ECL reagent and normalized by total ERK and total Akt (pERK/tERK: n = 7 and 5 biological replicates in Control and FGFR1/KO groups, respectively; pAkt/tAkt: n = 4 biological replicates for each genotype; analyzed by 2-tailed two-sample t-test. pERK/tERK: p = 0.017, pAKT/tAkt: ns). B Representative anti-MyHC/anti-Desmin IF stainings of SC-derived primary myoblasts derived isolated from FGFR1/4 KO mice via MACS (FGFR1/4 KO -TMX: untreated, top panels; FGFR1/4 KO + TMX: treated with 1 mM (Z)−4-hydroxytamoxifen for initial 48 h of culture, bottom panels) cultured in growth media with vehicle control (DMSO, left panels), ERK activator (PMA, middle panels), or Akt activator (SC79, right panels). 25,000 cells/cm.2 were seeded in each well of 8-well chambered slide. Pseudo-colored merged overlays (Green: Desmin, Orange: MyHC, Blue: DAPI) are shown. Scale bar (top right panel): 100 μm. C Quantification of fusion index of primary myoblasts cultured in growth media in (B) (n = 3 biological replicates; 424 ~ 677 nuclei quantified in each n. Analyzed by 2-tailed two-sample t-test. -TMX + DMSO vs + TMX + DMSO: p = 0.0044, + TMX + DMSO vs + TMX + PMA: p < 0.001. ns: not significant) FGFR1 and FGFR4 predominantly signal through the ERK effector pathway to drive SC proliferation and prevent precocious differentiation. A Western blotting on total protein extracts from in vitro cultured SC-derived primary myoblasts isolated via FACS from Control (Left) and FGFR1/4 KO (Right) mice. Phospho-ERK and phospho-AKT signals were detected by ECL reagent and normalized by total ERK and total Akt (pERK/tERK: n = 7 and 5 biological replicates in Control and FGFR1/KO groups, respectively; pAkt/tAkt: n = 4 biological replicates for each genotype; analyzed by 2-tailed two-sample t-test. pERK/tERK: p = 0.017, pAKT/tAkt: ns). B Representative anti-MyHC/anti-Desmin IF stainings of SC-derived primary myoblasts derived isolated from FGFR1/4 KO mice via MACS (FGFR1/4 KO -TMX: untreated, top panels; FGFR1/4 KO + TMX: treated with 1 mM (Z)−4-hydroxytamoxifen for initial 48 h of culture, bottom panels) cultured in growth media with vehicle control (DMSO, left panels), ERK activator (PMA, middle panels), or Akt activator (SC79, right panels). 25,000 cells/cm.2 were seeded in each well of 8-well chambered slide. Pseudo-colored merged overlays (Green: Desmin, Orange: MyHC, Blue: DAPI) are shown. Scale bar (top right panel): 100 μm. C Quantification of fusion index of primary myoblasts cultured in growth media in (B) (n = 3 biological replicates; 424 ~ 677 nuclei quantified in each n. Analyzed by 2-tailed two-sample t-test. -TMX + DMSO vs + TMX + DMSO: p = 0.0044, + TMX + DMSO vs + TMX + PMA: p < 0.001. ns: not significant) Discussion Preserving SCs in quiescence, a reversible growth arrest state, is essential for retaining their capacity to rapidly activate, proliferate and differentiate to contribute new myonuclei for regenerative myofiber after trauma. This quiescent state needs to be actively maintained by cell-intrinsic and -extrinsic regulatory signaling networks. While several cell signaling pathways including Notch, Calcitonin, and Integrin-β1 have emerged as contributors to this regulation [4–9], our knowledge on the molecular regulation of SC quiescence is still incomplete. Here, we provide the first evidence that FGFR1/4 signaling is required for maintaining long-term SC quiescence via preventing the precocious differentiation of SCs during homeostasis. Moreover, we discover that FGFR1/4 are critical for effective muscle regeneration and SC self-renewal. Mechanistically, FGFR1/4 coordinate amplification of the SC lineage via recruitment of the ERK signaling pathway to prevent cell cycle exit and terminal differentiation. Our findings identify a dual role for FGFR signaling in the molecular regulation of SCs, i.e. safeguarding quiescence during homeostasis and ensuring SC-lineage amplification for generating appropriate numbers of new myonuclei during regenerative myogenesis. Previous studies on FGF signaling mainly focused on the proliferation or differentiation stages of myoblasts, but little is known about its role in the quiescent SCs. Previously, we investigated the contributions of FGF6 to the regulation of the quiescent SC pool in the adult and discovered significantly reduced SC numbers in adult Fgf6 mutant mice [40]. However, this decrease results at least in part from the reduced SC expansion during early postnatal development as the Fgf6 null mouse was based on a constitutive deletion. Here, we generated an inducible SC-specific mouse model for concomitant inactivation of both Fgfr1 and Fgfr4 in the adult. We discover that Fgfr1/4 dually deficient SCs fail to maintain quiescence and remarkably undergo terminal differentiation within their niche during normal tissue homeostasis. These findings establish a previously unappreciated role for FGFR signaling in the maintenance of SC quiescence. SC-specific inactivation of the Notch effector, recombination signal binding protein for immunoglobulin kappa J region (RBP-J), resulted in precocious expression of Myogenin, indicating spontaneous differentiation of SCs in uninjured muscles. Moreover, muscle regeneration was impaired, and SC self-renewal was decreased in these mice [5, 6]. Loss of Calcitonin receptor caused SCs to spontaneously break quiescence and enter the cell cycle. By contrast, Calcitonin receptor-deficient SCs undergo apoptosis and/or leave their niche under the basal lamina of muscle fibers [7]. Integrin-β1-deficient SCs spontaneously differentiate during homeostasis and fail to regenerate muscle tissue after acute injury stemming from compromised SC proliferative capacity. Moreover, restoration of Integrin-β1 signaling could rescue the reduced FGF-2 sensitivity in aged SCs [9, 52]. SC-specific loss of Fgfr1/4 results in aberrant precocious SC differentiation within an intact niche, comparable to SC-specific RBP-J deficiency and Integrin-β1 deficiency, suggesting that these signaling pathways may converge on similar mechanisms to maintain SC quiescence and regenerative capacity. We also found that acute injury-induced muscle regeneration was compromised after dual inactivation of Fgfr1 and Fgfr4 specifically in SCs. The regenerated muscle fiber cross-sectional area is largely unaffected in the early stages of regeneration (7 DPI) but is significantly decreased in FGFR1/4 KO mice during later stages (28 DPI). The impaired regeneration phenotype at later timepoints after injury is consistent with our analysis of regenerative capacity in Fgf6 mutant mice, which also show no impairment in the genesis of early regenerative myotubes but regenerative myofiber size is compromised late in regeneration [40]. Here, we demonstrate that FGFR1 and FGFR4 maintain the proliferative status of activated myoblasts and prevent their precocious differentiation. In vivo, this may translate to sufficient numbers of differentiating myoblasts at early timepoints in injury-induced muscle regeneration but at the expense of not having adequate SC amplification for supplying the required numbers of new myonuclei to support regenerative myofiber growth at later regeneration timepoints. The FGF signaling pathway can activate downstream signal transducers including ERK1/2 and Akt to regulate diverse cellular functions. However, the main downstream effector targeted by FGFR1 and FGFR4 signaling in SCs or myoblasts has not been defined. Here, we found that ERK1/2 activity is decreased in Fgfr1/4 dually deficient SC-derived myoblasts. Interestingly, Eigler et al. observed that pharmacological inhibition of ERK induced precocious differentiation of mouse primary myoblasts in vitro despite maintaining cells in growth promoting medium, consistent with our precocious differentiation phenotype of Fgfr1/4 dually deficient myoblasts [53]. Cdon, a component of cell adhesion complexes, was reported to interact and regulate FGFR1 and FGFR4 surface localization in SCs. Ablation of Cdon in SCs resulted in decreased ERK signaling activity, raising the possibility that FGFR1/4 signaling is critical for regulating ERK1/2 activity in the SC lineage [54]. Here, we demonstrate that the precocious differentiation phenotype caused by Fgfr1/4 inactivation could be rescued by pharmacological stimulation of ERK phosphorylation while attempted rescue via forced Akt phosphorylation failed. These data support that FGFR1 and FGFR4 predominantly utilize ERK signaling to inhibit precocious differentiation and instead drive amplification of the SC lineage. Previous studies reported decreases in SC numbers during aging [20, 22]. Moreover, Bernet et al. found that FGF2 sensitivity by FGFR1 was reduced in aged SCs during muscle regeneration [52]. Here, we discovered that FGFR1/4 are required for quiescent SC pool maintenance, which raises the possibility that the decreased FGFR1 sensitivity in SCs could contribute to diminishing SC numbers during aging. Future studies are needed to elucidate the role of FGFR1/4 in the regulation of quiescent SCs during aging via SC-specific Fgfr1/4 inactivation or forced activation of FGFR signaling in aged mice. FGFR1 and FGFR4 are the FGFR family members predominantly expressed in SCs [42, 44, 45]. Gene inactivation targeting either FGF receptor individually via either myogenic lineage-specific knockout of Fgfr1 or germline inactivation of Fgfr4 resulted in much less severe SC and muscle regeneration phenotypes compared to the dramatic loss in SCs after dual Fgfr1/4 inactivation reported here [42, 46]. Myogenic-lineage-specific Fgfr1 inactivation via a constitutive MyodCre knockin allele resulted in a modest delay of the muscle regeneration process and had no significant impact on SC numbers [42]. Similarly, in Fgfr4 germline mutant mice, a slight initial delay in muscle regeneration at 7 days post-injury appears to be largely compensated for by 14 days [46]. Taken together with the matching high binding affinity to a similar complement of FGF ligands [37], the much more pronounced effects on quiescent SC maintenance and muscle regeneration we observe after SC-specific dual inactivation of Fgfr1/4 in the adult suggest that to a significant extent, FGFR1 and FGFR4 act redundantly in relaying the FGF signals during both SC quiescence and SC-mediated muscle regeneration. In conclusion, our study demonstrates that the combined contributions of Fgfr1 and Fgfr4 are essential for quiescence maintenance in SCs and for promoting amplification of the activated SC-derived myoblast lineage. FGFR1/R4 signaling is required to inhibit precocious differentiation of quiescent SCs as well as cell cycle exit and terminal differentiation of the activated SC lineage via engaging the ERK signaling axis. These findings identify FGFR1 and FGFR4 as potential targets for development of new therapies to improve skeletal muscle regeneration. Experimental procedures Animals The Fgfr1flox/flox;Fgfr4floxflox ‘double-floxed’ mouse strain was provided by Dr. Zipora Yablonka-Reuveni. Floxed Fgfr1 mice were generated and described previously [42, 55]. Floxed Fgfr4 mice were generated in the Yablonka-Reuveni laboratory via mating Fgfr4tm1a(EUCOMM)Wtsi mice (obtained from the International Mouse Phenotyping Consortium (IMPC)) with the FLPo deleter strain (B6.129S4-Gt(ROSA)26Sortm2(FLP*)Sor/J, obtained from the Jackson Laboratory) (Figure S5). Recombination at flp sites was confirmed via PCR. Appropriate mouse matings were performed to remove the R26FLP allele and combine the Fgfr1flox and Fgfr4flox alleles to generate Fgfr1flox/flox;Fgfr4flox/flox mice. Pax7CE mice (B6;129-Pax7tm2.1(cre/ERT2)Fan/J) were generated and characterized by us previously [56]. To adequately control for potential effects of Pax7 heterozygosity, all mice used for controls in this study are also heterozygous, i.e. Pax7CE/+. R26ReYFP mice (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J) were obtained from the Jackson Laboratory [57]. Anesthesia was performed via inhalation of isoflurane (induction with 5% and maintenance with 2%, Henry Schein NDC11695-6776–2). Mice were genotyped via PCR on ear clip samples. All animals and procedures were approved by IACUC protocol # 2018A00000136. Tamoxifen for in vivo and cell culture studies To induce CreERT2-mediated loxP recombination in vivo, tamoxifen (20 mg/mL in corn oil (Sigma T5648)) at 3 mg/40 g body weight was administered to mice per intraperitoneal injection once a day for 5 consecutive days, as done by us previously [12]. SCs isolated via MACS (see below) and isolated myofibers were treated with (Z)−4-hydroxytamoxifen (1 μM, Sigma 579,002) for the initial 48 h of culture to inactivate Fgfr1 and Fgfr4. Muscle injury For injury-induced muscle regeneration experiments, adult mice were anesthetized by isoflurane (induction with 5% and maintenance with 2%; Henry Schein NDC11695-6776–2) and 30 μL of cardiotoxin (5 μM in pharmaceutical grade normal saline; Sigma-Aldrich C9759) was injected into the tibialis anterior muscle, as done by us previously [40]. EdU On day 2, 3, and 4 after muscle injury, EdU (1 mg/mL in saline, at 0.1 mg/20 g body weight, Thermo Fisher A10044) was administered to mice by intraperitoneal injection, as done by us previously [12]. For labeling of primary myoblasts in monolayer or single myofiber culture, EdU was added to the media to a final concentration of 10 µM two hours (myoblasts) or four hours (single myofiber) prior to fixing cells with PFA. EdU detection was performed using the Click-iT EdU cell proliferation assay kit according to manufacturer’s instructions (Thermo Fisher C10340). Single muscle fiber isolation and culture Single myofiber explant cultures were performed as done by us previously [58]. In brief, extensor digitorum longus (EDL) muscles were isolated from 2-month-old mice and digested with collagenase I (Worthington LS0004196, 0.2% in DMEM). The digested muscles were transferred into tituration medium (DMEM (Sigma-Aldrich D6249), 10% Fetal bovine serum (FBS, Cytiva SH30071.03), 1% Penicillin–Streptomycin (PS, Gibco 15,140,122)) and titurated with a glass Pasteur pipette to release individual muscle fibers. The single muscle fibers were then cultured and fixed at 0 or 72 h post-tituration with 4% paraformaldehyde (Sigma-Aldrich 158,127) in PBS. Muscle dissection and digestion Muscle dissection and digestion was performed as done by previously [58]. In brief, muscles from upper and lower hindlimbs were dissected from 2-month-old mice and digested with collagenase II (Worthington S004176, 1000U/mL) in wash media (Ham’s F-10 medium (Gibco 10,550,043), 10% horse serum, 1% PS) in a 37 °C water bath with agitation for 90 min. Following digestion with collagenase, samples were centrifuged at 500 g for 10 min at 4 °C, and samples were resuspended in wash media containing collagenase II (100U/mL) and Dispase (1.1U/mL, Gibco 17,105,041) and digested in 37 °C water bath with agitation for an additional 30 min. Following digestion, a 30-mL syringe and 20-gauge needle were used to draw and eject the digested muscle samples for 10 times. The samples were then filtered by 40-μm nylon cell strainer, centrifuged at 500 g for 10 min at 4 °C, and cell pellets were resuspended in growth media for cell culture or wash media for SC isolation by either FACS or MACS. Fluorescence-activated cell sorting (FACS) SC isolation by FACS was performed on a BD FACSAria™ III. The gating strategy included selection of cell singlets, which were further gated for YFP expression (from recombined Rosa26eYFP reporter allele). Gating for YFP positive cells was stringently performed to achieve minimal purity of 99.5% (via comparison to YFP negative muscle samples). Sorted cells were centrifuged and resuspended in appropriate amounts of myoblast growth medium and seeded on Matrigel-coated dishes or plates for in vitro culture. Magnetic-activated cell sorting (MACS) Digested muscle samples were centrifuged at 500 g for 10 min at 4 °C, supernatant was removed, and cell pellets were resuspended with 2 mL MACS buffer (2 mM EDTA and 0.5% BSA in 1 × PBS). Samples were centrifuged again, and supernatant was removed. 160 μL MACS buffer was used to resuspend cells and 40 μL satellite cell isolation kit (mouse) beads (Miltenyi Biotec 130–104–268) were added. Samples were mixed and incubated on a rotator at 4 °C for 15 min. A MACS LS column was set up on a magnetic with a waste tube under it. Columns were washed with 3 mL MACS buffer. Waste tube was replaced with a collection tube, column was rinsed with 0.5 mL MACS buffer, cell-bead mixture was added to column, and 1.5 mL MACS buffer was added. The samples were passed through the column via gravity flow. Collected flow-through samples were centrifuged at 500 g for 10 min at 4 °C and cell pellets were resuspended with 80 μL MACS buffer, to which 20 μL satellite cell isolation kit (mouse) beads were added, and samples were mixed. The negative selection step was repeated. Afterwards, 80 μL MACS buffer was used to resuspend cells and 20 μL anti-integrin α−7 beads (Miltenyi Biotec 130–104–261) were added. Samples were mixed and incubated on a rotator at 4 °C for 15 min. A MACS MS column was set up on magnet with a waste tube under it. Columns were washed with 1 mL MACS buffer. The cell-bead mixture was added to column and 1.5 mL MACS buffer was added. The samples were passed through the column via gravity flow. Waste tubes were replaced with collection tubes, MS columns were removed from magnet, and 1.5 mL MACS buffer was added to each column. A plunger was used to quickly push buffer through column into collection tube. Collected samples were centrifuged at 500 g for 10 min at 4°C. Cells were resuspended with appropriate amount of myoblast growth medium and seeded on Matrigel-coated cell culture dishes for in vitro culture. Myoblast culture Isolated primary myoblasts were cultured in myoblast growth medium (Ham’s F-10 medium, 10% horse serum, 0.5% chick embryo extract (MP Biomedicals 92,850,145), 1% PS, 2.5 ng/mL bFGF (R&D systems 233-FB), on Matrigel (Corning 354,248, 10% in DMEM)-coated cell culture dishes. For the rescue experiment, DMSO (Sigma-Aldrich D2438), ERK activator PMA (Phorbol 12-myristate 13-acetate, 1 μM, SelleckChem S7791) or Akt activator SC79 (2.5 μM, SelleckChem S7863) were added to the culture medium from day 3 after myoblast isolation until the end of experiment. Histology Histology was performed as done by previously [40]. 10-μm muscle cryo-sections were collected on microscopy glass slides and fixed in 100% ethanol at room temperature for 30 s followed by a wash with tap water for 1 min. Next, samples were stained with Gill’s Hematoxylin (Sigma-Aldrich GHS232) for 4.5 min, washed under running lukewarm tap water for 5 min, incubated with Scott’s tap water for 10 s and washed with tap water for 1 min. Samples were then stained with Eosin (Sigma-Aldrich HT110132) for 45 s and washed under running tap water until water was running clear. After that, samples were sequentially rinsed with ethanol (70% 4 dips, 90% 7 dips, 100% 10 dips) and Xylene (Thermo Fisher X3P, 2 tanks, 10 dips in each tank). Slides were mounted in Permount mounting medium (Thermo Fisher SP15) using plastic cover slips. All images were obtained via bright-field microscopy using a ToupCam camera (UCMOS05100KPA). Immunofluorescent (IF) staining IF stainings were performed as done by previously [40]. All samples including 10-μm muscle cryo-sections, isolated single muscle fibers, and primary myoblasts on cell culture chamber slides were fixed with paraformaldehyde. Muscle cryo-sections were fixed in 4% PFA on ice for 5 min, single muscle fibers were fixed in 4% PFA at room temperature for 10 min, and primary myoblasts were fixed in 2% PFA at room temperature for 10 min. Samples were washed twice in PBS at room temperature for 10 min each. Next, they were permeabilized with permeabilization buffer (tissue sections and myoblasts in 0.3% Triton X-100 in PBS (0.3% PBT) for 20 and 10 min, respectively; single myofibers in 0.5% Triton X-100 in PBS (0.5% PBT) for 15 min). Samples were then washed with 0.05% PBT for 5 min. Subsequently, tissues sections were incubated with Mouse on Mouse Blocking Reagent (Vector Laboratories BMK-2202) at room temperature in humidified chamber for a minimum of 3 h and up to 8 h. After that, samples were incubated in blocking solution (0.5% Blocking Powder (Perkin Elmer FP1012) + 10% heat-inactivated goat serum (Thermo Fisher 50062Z) in 0.05% PBT) at room temperature for 1 h. The samples were then incubated with primary antibodies diluted in blocking solution at 4 °C overnight. The next day, after washing with 0.05% PBT at room temperature for 3 times 10 min each, samples were incubated with secondary antibodies diluted in blocking solution at room temperature for 1 h. If the samples were labeled with EdU, they were further incubated with EdU detection reagent (see EdU) at room temperature for 30 min. Samples were counterstained with DAPI (1 µg/mL in 0.05% PBT, Thermo Fisher D1306) and washed with 0.05% PBT at room temperature for 3 times 10 min each. Myofibers were transferred from Eppendorf tubes to glass microscopy slides. Slides were mounted with Fluoromount (Southern Biotech 0100–01) using plastic coverslips and sealed with nail polish. All IF images were acquired by a Zeiss Axioscope microscope and a Zeiss AxioCam monochrome charge-coupled device (CCD) camera, a Nikon Ti2 Eclipse microscope and Nikon DS-Ri2 camera, or an Invitrogen EVOS FL auto2 microscope. TUNEL assay TUNEL assay was performed using Click-iT™ Plus TUNEL Assay (Invitrogen C10619) following the manufacturer’s protocol. Western Blotting Cells were lysed by RIPA buffer containing 1% proteinase inhibitor (Thermo Fisher A32965). The cell lysate was mixed with 4X Laemmli sample and boiled at 95℃ for 10 min. Samples were then subjected to polyacrylamide gel electrophoresis and proteins were transferred onto nitrocellulose membranes (Bio-Rad l1620112). Membranes were washed with TBS-T and subsequently stained with Ponceau S solution (Thermo Fisher A40000279) for ~ 1 min and imaged via Bio-Rad ChemiDoc MP imaging system. Following, membranes were washed with TBS-T until Ponceau S staining was no longer evident. Membranes were incubated with blocking buffer (5% milk in TBS-T) for 1 h. After that, membranes were incubated with primary antibodies diluted in blocking buffer at 4℃ overnight. The next day, after washing with TBS-T at room temperature for 3 times, samples were incubated with secondary antibodies diluted in blocking buffer at room temperature for 1 h. After washing with TBS-T for 3 times, membranes were incubated with ECL reagent (Cytiva RPN2209) for 1 min and luminescence signal was detected by Bio-Rad ChemiDoc MP imaging system. Primary antibodies for immunofluorescenceAntigenHost/IsotypeDilutionBrand/catalog numberRRIDPax7Mouse IgG11:5DSHB PAX7AB_528428MyoDMouse IgG2b1:200Santa Cruz sc-377460AB_2813894Myogenin,Mouse IgG11:20DSHB F5DAB_2146602MyHCMouse IgG2b1:20DSHB MF-20AB_2147781LamininRabbit1:1000Sigma L9393AB_477163LamininChicken1:1000LifeSpan BioSciencesLS-C96142AB_2134058YFP/GFPRabbit1:1000Thermo Fisher G10362AB_2536526YFP/GFPChicken1:1000Abcam AB13970AB_300798FGFR1Rabbit1:200Cell Signaling 9740AB_11178519DesminRabbit1:200Thermo Fisher PA5-16,705AB_10977258Cleaved caspase-3Rabbit1:200Cell Signaling 9664AB_2070042 AntigenHost/IsotypeDilutionBrand/catalog numberRRIDPax7Mouse IgG11:5DSHB PAX7AB_528428MyoDMouse IgG2b1:200Santa Cruz sc-377460AB_2813894Myogenin,Mouse IgG11:20DSHB F5DAB_2146602MyHCMouse IgG2b1:20DSHB MF-20AB_2147781LamininRabbit1:1000Sigma L9393AB_477163LamininChicken1:1000LifeSpan BioSciencesLS-C96142AB_2134058YFP/GFPRabbit1:1000Thermo Fisher G10362AB_2536526YFP/GFPChicken1:1000Abcam AB13970AB_300798FGFR1Rabbit1:200Cell Signaling 9740AB_11178519DesminRabbit1:200Thermo Fisher PA5-16,705AB_10977258Cleaved caspase-3Rabbit1:200Cell Signaling 9664AB_2070042 LifeSpan BioSciences LS-C96142 Secondary antibodiesAntigenFluorophoreDilutionBrand/catalog numberRRIDMouse IgG1Alexa Fluor 5681:1000Invitrogen A21124AB_141611Mouse IgG2bAlexa Fluor 4881:1000Invitrogen A21141AB_141626Mouse IgG2bAlexa Fluor 6471:1000Thermo Fisher A21242AB_2535811Rabbit Ig?Alexa Fluor 4881:1000Thermo Fisher 35,552AB_844398Rabbit IgGAlexa Fluor 6471:1000Invitrogen A21244AB_2535812Chicken IgYAlexa Fluor 6471:1000Thermo Fisher A32933AB_2762845 AntigenFluorophoreDilutionBrand/catalog numberRRIDMouse IgG1Alexa Fluor 5681:1000Invitrogen A21124AB_141611Mouse IgG2bAlexa Fluor 4881:1000Invitrogen A21141AB_141626Mouse IgG2bAlexa Fluor 6471:1000Thermo Fisher A21242AB_2535811Rabbit Ig?Alexa Fluor 4881:1000Thermo Fisher 35,552AB_844398Rabbit IgGAlexa Fluor 6471:1000Invitrogen A21244AB_2535812Chicken IgYAlexa Fluor 6471:1000Thermo Fisher A32933AB_2762845 Primary antibodies for Western blotAntigenHost/IsotypeDilutionBrand/catalog numberRRIDphospho-ERK1/2Rabbit1:2000Cell Signaling 4370AB_2315112phospho-AktRabbit1:2000Cell Signaling 4060AB_2315049 AntigenHost/IsotypeDilutionBrand/catalog numberRRIDphospho-ERK1/2Rabbit1:2000Cell Signaling 4370AB_2315112phospho-AktRabbit1:2000Cell Signaling 4060AB_2315049 Secondary antibodies for Western blotAntigenConjugateDilutionBrand/catalog numberRabbit IgGHRP1:5000Cytiva NA934AB_772206 AntigenConjugateDilutionBrand/catalog numberRabbit IgGHRP1:5000Cytiva NA934AB_772206 Quantifications All quantifications were performed blinded to the samples’ genotypes. All IF monochrome images were pseudo-colored and overlayed in ImageJ (RRID: SCR_003070). Central nucleation and size of muscle fibers were determined by analyzing anti-laminin and DAPI stained IF images using Cellpose software (RRID:SCR_021716) [59]. SC quantifications were performed as done by us previously [40]. In brief, SC detection was conducted using IF staining on 10-μm cross-sections with anti-PAX7 and anti-Laminin, followed by DAPI counterstaining. To minimize bias, images were first captured for anti-Laminin, then anti-PAX7, at 20X magnification. Channels were overlaid in ImageJ, and sub-laminal PAX7+ SCs were manually counted. Statistics GraphPad Prism (RRID:SCR_002798) was used to create bar graphs. All data were presented as mean ± standard deviation. Difference between groups was analyzed by 2-tailed t-tests (P < 0.05 was determined as statistically significant). Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 1. Supplementary Material 2.